Selected publications
The genotype of the original Wiskott phenotype. Binder V, Albert MH, Kabus M, Bertone M, Meindl A, and Belohradsky BH (2006). N Engl J Med 355, 1790-1793.
Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Gefen N*, Binder V*, Zaliova M, Linka Y, Morrow M, Novosel A, Edry L, Hertzberg L, Shomron N, Williams O, Trka J, Borkhardt A, and Izraeli S (2010). Leukemia 24, 89-96. * Both authors contributed equally to this work
High throughput in vivo phenotyping: The zebrafish as tool for drug discovery for hematopoietic stem cells and cancer. Binder V, and Zon LI (2012). Drug Discovery Today: Disease Models.
A new workflow for whole-genome sequencing of single human cells. Binder V*, Bartenhagen C*, Okpanyi V, Gombert M, Moehlendick B, Behrens B, Klein HU, Rieder H, Ida Krell PF, Dugas M, Stoecklein NH, and Borkhardt A (2014). Hum Mutat 35, 1260-1270. * Both authors contributed equally to this work
Epoxyeicosatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment. Li P*, Lahvic JL*, Binder V*, Pugach EK, Riley EB, Tamplin OJ, Panigrahy D, Bowman TV, Barrett FG, Heffner GC, McKinney-Freeman S, Schlaeger TM, Daley GQ, Zeldin DC, and Zon LI (2015). Nature 523, 468-471.* These authors contributed equally to this work
All Publications Binder Lab
